Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29306855 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL25041163 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL5443444 | 0.98 | L3MBTL1 (0.49) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL17423690 | 0.84 | LGALS1 (0.50) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL116442 | 0.84 | LGALS1 (0.50) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL5527338 | 0.84 | LGALS1 (0.50) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL11573310 | 0.82 | L3MBTL1 (0.49) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL22511426 | 0.81 | L3MBTL1 (0.47) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL24437634 | 0.81 | L3MBTL1 (0.47) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL31019382 | 0.80 | L3MBTL1 (0.47) | L3MBTL1MAPTLGALS1LGALS3LGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | BARCLAYS BANK PLC (GB) | 2022-01-20 | — | — | US | disclosed |
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20210024923-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-10883104-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190055554-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | US | disclosed |
| US-9957292-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9943604-B2 | Targeted therapeutic nucleosides and their use | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, LDLR | L3MBTL1 2402/4885MAPT 1766/4885LGALS1 57/4885 |
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | PMM2, DPM1, BPGM | L3MBTL1 628/4885MAPT 812/4885LGALS1 128/4885 |
| US-20190055554-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | L3MBTL1 2462/4885MAPT 4055/4885LGALS1 23/4885 |
| US-20210024923-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | L3MBTL1 1482/4885MAPT 610/4885LGALS1 49/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | L3MBTL1 1482/4885MAPT 610/4885LGALS1 49/4885 |
| US-10883104-B2 | Compositions and methods for modulating apolipoprotein (a) expression | APOB, APOL1, LDLR | L3MBTL1 1288/4885MAPT 2232/4885LGALS1 45/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | L3MBTL1 198/4885MAPT 1930/4885LGALS1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.